Anteris Technologies Global Quick Ratio (AVR) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket
 


Anteris Technologies Global Corp   (AVR)

Anteris Technologies Global 's Quick Ratio

AVR's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Anteris Technologies Global 's Cash & cash equivalent grew by % in the Q2 2026 sequentially, faster than Current Liabilities, this led to improvement in Anteris Technologies Global 's Quick Ratio to 14.02 a new company high.

Within Medical Equipment & Supplies industry 5 other companies have achieved higher Quick Ratio than Anteris Technologies Global in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 0 to 283.

Explain Quick Ratio?
How much Cash & cash equivalents AVR´s has?
What are AVR´s Current Liabilities?




AVR Quick Ratio (Jun 30 2026)
Q2
(Mar 31 2026)
Q1
(Dec 31 2025)
Q4
(Sep 30 2025)
Q3
(Jun 30 2025)
Q2
Y / Y Current Liabilities Change 64.37 % -5.94 % 0 % - -
Y / Y Cash & cash equivalent Change - - -90.5 % - -
Quick Ratio MRQ 14.02 - 0.57 - -
AVR's Total Ranking # 283 # 0 # # #
Seq. Current Liabilities Change 40.26 % 10.73 % -7.6 % 14.55 % -19.73 %
Seq. Cash & cash equivalent Change - - - - -



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 6
Healthcare Sector # 110
Overall Market # 283


Quick Ratio Statistics
High Average Low
14.02 7.36 3.52
(Jun 30 2026)   (Mar 31 2025)




Financial Statements
Anteris Technologies Global 's Current Liabilities $ 18 Millions Visit AVR's Balance sheet
Anteris Technologies Global 's Cash & cash equivalent $ 257 Millions Visit AVR's Balance sheet
Source of AVR's Sales Visit AVR's Sales by Geography


Cumulative Anteris Technologies Global 's Quick Ratio

AVR's Quick Ratio for the trailling 12 Months

AVR Quick Ratio

(Jun 30 2026)
12 Months
(Mar 31 2026)
12 Months
(Dec 31 2025)
12 Months
(Sep 30 2025)
12 Months
(Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 51.91 % 89.9 % 320.43 % - -
Y / Y Cash & cash equivalent TTM Growth 121.15 % -94.39 % -21.01 % - -
Quick Ratio TTM 4.71 0.14 1.12 2.4 3.24
Total Ranking TTM # 3647 # 3963 # # #
Seq. Current Liabilities TTM Growth 14.71 % -1.66 % 0 % 34.67 % 43.4 %
Seq. Cash & cash equivalent TTM Growth 3843.29 % -87.97 % -53.4 % 0 % 0 %


On the trailing twelve months basis AVR Cash & cash equivalent remained unchanged by % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Anteris Technologies Global 's Quick Ratio to 4.71, above AVR average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Equipment & Supplies industry 193 other companies have achieved higher Quick Ratio than Anteris Technologies Global . While Quick Ratio overall ranking has improved so far to 3647, from total ranking during the twelve months ending first quarter 2026 at 3963.

Explain Quick Ratio?
How much Cash & cash equivalents AVR´s has?
What are AVR´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Medical Equipment & Supplies Industry # 194
Healthcare Sector # 865
Within the Market # 3647


trailing twelve months Quick Ratio Statistics
High Average Low
5.28 2.86 1.24
(Jun 30 2026)   (Mar 31 2026)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Medical Equipment & Supplies Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Microbot Medical Inc   34.10 $ 132.596  Millions$ 3.888  Millions
Global Innovative Platforms Inc.  31.35 $ 0.244  Millions$ 0.008  Millions
Anteris Technologies Global Corp   14.02 $ 257.385  Millions$ 18.360  Millions
Heartflow Inc   13.95 $ 615.238  Millions$ 44.088  Millions
Ceribell Inc   13.13 $ 225.898  Millions$ 17.200  Millions
Perspective Therapeutics Inc   12.80 $ 467.708  Millions$ 36.544  Millions
Lemaitre Vascular Inc   12.57 $ 376.240  Millions$ 29.935  Millions
Mobia Medical Inc   12.24 $ 177.090  Millions$ 14.472  Millions
Envveno Medical Corporation  11.39 $ 21.486  Millions$ 1.887  Millions
Pulse Biosciences Inc   9.26 $ 101.620  Millions$ 10.978  Millions
Orchestra Biomed Holdings Inc   8.16 $ 109.963  Millions$ 13.471  Millions
Biolife Solutions Inc   8.11 $ 113.100  Millions$ 13.947  Millions
Bone Biologics Corporation  7.87 $ 4.032  Millions$ 0.512  Millions
Beyond Air Inc   7.68 $ 26.340  Millions$ 3.428  Millions
Talkspace Inc   7.62 $ 90.998  Millions$ 11.937  Millions
Safe Pro Group Inc   7.24 $ 10.231  Millions$ 1.413  Millions
Delcath Systems Inc   7.22 $ 95.902  Millions$ 13.279  Millions
Streamex Corp   7.16 $ 18.586  Millions$ 2.595  Millions
Endra Life Sciences Inc  7.04 $ 5.540  Millions$ 0.787  Millions
Iradimed Corporation  6.45 $ 59.080  Millions$ 9.164  Millions
Orasure Technologies Inc  6.39 $ 160.582  Millions$ 25.119  Millions
Alpha Pro Tech Ltd   5.94 $ 18.901  Millions$ 3.180  Millions
Si bone inc   5.89 $ 141.519  Millions$ 24.042  Millions
Dexcom Inc   5.84 $ 1,107.000  Millions$ 189.500  Millions
Cvrx inc   5.78 $ 64.586  Millions$ 11.177  Millions
Carlsmed Inc   5.67 $ 70.244  Millions$ 12.397  Millions
Profound Medical Corp   5.24 $ 38.271  Millions$ 7.304  Millions
Rxsight Inc   5.03 $ 404.247  Millions$ 80.444  Millions
Transmedics Group Inc   4.81 $ 472.675  Millions$ 98.283  Millions
Aethlon Medical Inc   4.76 $ 4.934  Millions$ 1.036  Millions

Date modified: 2026-09-05T14:56:35+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.